Tradename: LOTEMAX

Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%
Status: Active, not recruiting Condition: Dry Eyes

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis
Status: Active, not recruiting Condition: Meibomian Gland Dysfunction; Posterior Blepharitis

Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
Status: Completed Condition: Allergic Conjunctivitis

Lotemax® Gel 0.5% and Restasis 0.05% in Subjects With Mild or Moderate Keratoconjunctivitis Sicca
Status: Not yet recruiting Condition: Keratoconjunctivitis Sicca

Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis
Status: Completed Condition: Conjunctivitis

Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery
Status: Active, not recruiting Condition: Pseudophakia; Inflammation

Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye
Status: Completed Condition: Dry Eye

Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
Status: Completed Condition: Allergic Conjunctivitis

A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin
Status: Completed Condition: Ocular Hypertension

Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection
Status: Not yet recruiting Condition: Ocular Inflammation; Infection Associated Blepharitis; Keratitis; Conjunctivitis, Bacterial